Key clinical point : Reduced-dose decitabine (DAC) could have a better response than reduced-dose azacitidine (AZA) in patients with myelodysplastic syndromes (MDS) with different prognostic risks.
Major finding: Overall response rate (ORR) was higher in the DAC (62.5%) than AZA (42.1%) group ( P = .007). Incidences of neutropenia ( P = .016) and infections ( P = .032) were higher in the DAC vs. AZA group.
Study details : Findings are from a retrospective study of 158 patients with MDS with varied prognostic risks who were administered reduced-dose of AZA (n=38) or DAC (n=120). Included patients received these hypomethylating agents for the first time between May 2006 and February 2020 and could not tolerate the standard doses.
Disclosures: The study was funded by the National Science and Technology Major Project of China . The authors declared no competing interests.
Source: Hu N et al. Med Sci Monit. 2021 Jan 30. doi: 10.12659/MSM.928454 .